Because of that the expression of AR in 786-O cells is increased after nilutamide therapy, but the expression of its downstream effector protein PSA is not affected, while the expression of p-Akt is lowered, and the malignant behavior of RCC cells is inhibited. The gene discussed is AR; the disease is renal cell carcinoma.